A Phase I Study of Combination Therapy With Didanosine (ddI) and Ribavirin in HIV-Infected Children.

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

Not specified

Study Completion Date

July 31, 1998

Conditions
HIV Infections
Interventions
DRUG

Ribavirin

DRUG

Didanosine

Trial Locations (15)

10032

Columbia Presbyterian Med Ctr, New York

Incarnation Children's Ctr / Columbia Presbyterian Med Ctr, New York

10037

Harlem Hosp Ctr, New York

10457

Bronx Lebanon Hosp Ctr, The Bronx

11040

Schneider Children's Hosp, New Hyde Park

20060

Howard Univ Hosp, Washington D.C.

27709

Glaxo Wellcome Inc, Research Triangle Park

32209

Univ of Florida Health Science Ctr / Pediatrics, Jacksonville

77030

Texas Children's Hosp / Baylor Univ, Houston

200102916

Children's Hosp of Washington DC, Washington D.C.

701122699

Tulane Univ / Charity Hosp of New Orleans, New Orleans

021155724

Children's Hosp of Boston, Boston

071032714

Univ of Medicine & Dentistry of New Jersey / Univ Hosp, Newark

071072198

Children's Hosp of New Jersey / UMDNJ - New Jersey Med Schl, Newark

009365067

Univ of Puerto Rico / Univ Children's Hosp AIDS, San Juan

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000833 - A Phase I Study of Combination Therapy With Didanosine (ddI) and Ribavirin in HIV-Infected Children. | Biotech Hunter | Biotech Hunter